B. Robert

发表

Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells

V. Denis, N. Vié, V. Copois, 2008, Molecular Cancer.

Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA

Franck Molina, Alain R. Thierry, Caroline Mollevi, 2014, Nature Medicine.

Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.

Cédric Leroy, B. Robert, S. Urbach, 2009, Cancer research.

TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT

E. Solary, B. Robert, C. Garrido, 2011, PloS one.

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors

B. Robert, P. Martineau, F. Bertolini, 2018, Theranostics.

Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells

B. Robert, G. Béhar, A. Pèlegrin, 2013, Molecular Cancer Therapeutics.

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer

B. Robert, P. Martineau, D. Bonenfant, 2018, EMBO molecular medicine.

B. Robert, A. Donda, A. Pèlegrin, 2005, Clinical Cancer Research.

B. Robert, A. Donda, C. Germain, 2005 .

Antithyroperoxidase antibody-dependent cytotoxicity in autoimmune thyroid disease.

B. Robert, B. Nguyen, S. Rebuffat, 2008, The Journal of clinical endocrinology and metabolism.

[Bispecific antibodies: what future?].

B. Robert, A. Pèlegrin, 2009, Medecine sciences : M/S.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

M. Ychou, B. Robert, F. Molina, 2013, Translational oncology.

[Strategies of tumor-pecific targeting based on the antigenic tumor specificities and the tumor microenvironment characteristics].

B. Robert, P. Martineau, Tristan Mangeat, 2020, Medecine sciences : M/S.

In vivo Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas

B. Robert, I. Navarro-Teulon, F. Bibeau, 2007, Clinical Cancer Research.

Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

N. Vié, B. Robert, M. Jarlier, 2013, Neoplasia.

Cancer Therapy: Preclinical TherapeuticActivityofAnti-AXLAntibodyagainst Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis

S. Manoir, N. Radosevic-Robin, B. Robert, 2017 .

Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis

N. Radosevic-Robin, B. Robert, C. Theillet, 2016, Clinical Cancer Research.

Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice.

B. Robert, P. Martineau, F. Bibeau, 2007, International journal of radiation oncology, biology, physics.

[Immunotargeting of tumors: state of the art and prospects in 2000].

B. Robert, L. Leserman, F. Buchegger, 2000, Bulletin du cancer.

Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer

B. Robert, P. Martineau, D. Bonenfant, 2022, Cancers.

Bispecific Antibodies for the Retargeting of Cytokines

B. Robert, A. Pèlegrin, J. Mach, 2011 .

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib‐resistant chronic myeloid leukaemia

B. Robert, V. Prouzet-Mauléon, E. Lippert, 2015, The Journal of pathology.

Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF

M. Ychou, B. Robert, C. Gongora, 2013 .

Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival

P. Colombo, B. Robert, P. Martineau, 2021, International journal of oncology.

Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells

P. Colombo, B. Robert, P. Martineau, 2021, Scientific Reports.

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

M. Ychou, B. Robert, P. Martineau, 2003, British Journal of Cancer.

Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells

V. Denis, N. Bec, B. Robert, 2022, PloS one.

Enhancement of 5‐fluorouracil cytotoxicity by human thymidine‐phosphorylase expression in cancer cells: In vitro and In vivo study

B. Robert, P. Cuq, A. Pèlegrin, 1999, International journal of cancer.

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO

B. Robert, B. Nguyen, S. Rebuffat, 2010, British Journal of Cancer.

Activation of neuronal FLT3 promotes exaggerated sensorial and emotional pain-related behaviors facilitating the transition from acute to chronic pain

B. Robert, P. Martineau, X. Capdevila, 2021, Progress in Neurobiology.

Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model

M. Ychou, B. Robert, A. Pèlegrin, 1999, British Journal of Cancer.

Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.

M. Ychou, B. Robert, A. Pèlegrin, 1996, Cancer research.

Active Antiviral T-Lymphocyte Response Can Be Redirected against Tumor Cells by Antitumor Antibody × MHC/Viral Peptide Conjugates

B. Robert, A. Donda, T. Filleron, 2006, Clinical Cancer Research.

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA)

B. Robert, F. Buchegger, A. Pèlegrin, 1999, International journal of cancer.

MiR-294/-302 promotes proliferation, suppresses G1-Srestriction point, and inhibits embryonic stem cell differentiationthrough separable mechanisms

B. Robert, M. Collin, A. Shenoy, 2013 .

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

A. Turtoi, B. Robert, P. Martineau, 2019, Journal of Immunotherapy for Cancer.

Upregulated flotillins and sphingosine kinase 2 derail AXL vesicular traffic to promote epithelial-mesenchymal transition.

S. Vacher, I. Bièche, B. Robert, 2022, Journal of cell science.

Flotillin-upregulation acts as an epithelial-mesenchymal transition driver by promoting sphingosine kinase 2-dependent AXL stabilization Running title : Upregulated-flotillins drive EMT via SphK2 and AXL

S. Vacher, I. Bièche, B. Robert, 2020 .

Upregulated-flotillins and sphingosine kinase 2 derail vesicular trafic to stabilize AXL and promote epithelial-mesenchymal transition

S. Vacher, I. Bièche, B. Robert, 2020, bioRxiv.

Epithelial-to-mesenchymal transition: EMT Plasma membrane: PM Receptor Tyrosine Kinases: RTKs Sphingosine kinase 2: SphK2 Sphingosine 1-phosphate: S1P Upregulated Flotillin-Induced Trafficking: UFIT

S. Vacher, I. Bièche, B. Robert, 2020 .

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts

M. Ychou, B. Robert, F. Molina, 2010, Nucleic acids research.

High Fragmentation Characterizes Tumour-Derived Circulating DNA

M. Ychou, B. Robert, F. Molina, 2011, PloS one.

Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump

M. Ychou, A. Causse, B. Robert, 2013, Molecular Cancer Therapeutics.

mediates Src invasive activity in advanced colon carcinoma cells.

B. Robert, S. Urbach, C. Leroy, 2009 .

SLAP displays tumour suppressor functions in colorectal cancer via destabilization of the SRC substrate EPHA2

B. Robert, F. Hollande, C. Leroy, 2014, Nature Communications.

Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.

B. Robert, I. Navarro-Teulon, A. Pèlegrin, 2008, Protein engineering, design & selection : PEDS.

Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial

M. Ychou, B. Robert, E. Crapez, 2015, Oncotarget.

[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].

S. Culine, M. Ychou, B. Robert, 2003, Bulletin du cancer.

In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.

B. Robert, A. Donda, F. J. Primus, 2003, Cancer immunity.

Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments.

B. Robert, P. Romero, J. Mach, 2001, Cancer immunity.

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

F. Penault-Llorca, N. Radosevic-Robin, B. Robert, 2014, Oncogene.

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

P. Colombo, F. Penault-Llorca, N. Radosevic-Robin, 2014, Oncotarget.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

C. Bascoul-Mollevi, B. Robert, A. Pèlegrin, 2012, Neoplasia.

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.

F. Penault-Llorca, C. Bascoul-Mollevi, B. Robert, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

MONOCLONALAND BISPECIFIC ANTIBODIES IN COMBINATIONWITH RADIOTHERAPYFOR CANCERTREATMENT

B. Robert, D. Azria, C. Larbouret, 2004 .

Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment

B. Robert, M. Ozsahin, A. Pèlegrin, 2004 .

Production of polyclonal antibodies against a wheat thioredoxinh by genetic immunization

B. Robert, M. Gautier, A. Pèlegrin, 1997, Plant Molecular Biology Reporter.

Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody.

André Pèlegrin, Sophie Gourgou, Pierre Martineau, 2003, International journal of radiation oncology, biology, physics.

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

G. Besra, B. Robert, H. Macdonald, 2008, The Journal of clinical investigation.

[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment].

B. Robert, E. Assenat, A. Pèlegrin, 2007, Bulletin du cancer.

Phase‐I/II radio‐immunotherapy study with iodine‐131‐labeled anti‐CEA monoclonal antibody F6 F(ab′)2 in patients with non‐resectable liver metastases from colorectal cancer

J. Rossi, M. Ychou, B. Robert, 1998, International journal of cancer.

[Biologic modulation of ionizing radiation by Toll-like receptors agonists: towards an increase in the therapeutic index of radiotherapy?].

B. Robert, O. Riou, D. Azria, 2012, Bulletin du cancer.

R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase.

B. Robert, A. Pèlegrin, C. Gauthier-Rouvière, 2008, Cancer research.

R-cadherin and myoblast transformation 1 R-cadherin expression inhibits myogenesis and induces myoblast transformation via Rac 1 GTPase

B. Robert, A. Pèlegrin, C. Gauthier-Rouvière, 2008 .

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

C. Bascoul-Mollevi, B. Robert, I. Navarro-Teulon, 2011, Breast Cancer Research.

A bispecific antibody to enhance radiotherapy by tumor necrosis factor-alpha in human CEA-expressing digestive tumors.

B. Robert, P. Martineau, S. Gourgou, 2004, International journal of radiation oncology, biology, physics.

Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.

P. Colombo, N. Vié, B. Robert, 2018, Cancer letters.

Epithelial-to-Mesenchymal Transition

S. Vacher, I. Bièche, B. Robert, 2020, Definitions.

Ann Oncol . Author Manuscript Combined Cetuximab and Trastuzumab Are Superior to Gemcitabine in the Treatment of Human Pancreatic Carcinoma Xenografts

C. Bascoul-Mollevi, B. Robert, I. Navarro-Teulon, 2022 .

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

G. Besra, B. Robert, L. Baldi, 2008, The Journal of clinical investigation.